Background Multiple sclerosis (MS) places a considerable financial burden on the society.
However, data quantifying the contemporary cost burden in France are lacking. Objective …

This review gives an overview of national registries that are currently in use for patients with
multiple sclerosis (MS). The large-scale registries described herein include the Danish MS …

Objective To evaluate the impact of drug diversity on treatment effectiveness in relapsing-
remitting multiple sclerosis (RRMS) in Germany. Design This study employs real-world data …

Background Multiple sclerosis (MS) is one of the most frequently observed neurological
conditions in Switzerland, but data sources for country-wide epidemiological trend …

Background: In Europe, there exists considerable variability in access to care and treatment
for multiple sclerosis (MS). Objectives: To improve this situation, we identified key issues …

Background: To assess the value of management strategies in multiple sclerosis (MS),
outcome data have to be combined with cost data. This requires that cost data be regularly …

Background In relapsing-remitting multiple sclerosis (RRMS) the most common treatment
strategy has been to start with low-moderate efficacy disease modifying therapy (LE-DMT) …

Aims and methodology Description of basic data, common symptoms and their medical, non-
drug and combined symptomatic treatment in a large sample of MS patients undergoing …

Introduction Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for
decades, frequently as off label licensed therapies. Given the new MS treatment landscape …

Background Several disease-modifying therapies (DMTs) treat relapsing–remitting multiple
sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Few comprehensive …